CRTC2 and metabolic dysfunction-associated steatotic liver disease: Furthermore, HFD-induced activation of CRTC2 increases miR-34a/mTOR activity in the liver, promoting NAFLD via the induction of lipogenesis and the inhibition of lipophagy98 (Fig. 3B).